Edition:
India

Adamis Pharmaceuticals Corp (ADMP.OQ)

ADMP.OQ on NASDAQ Stock Exchange Capital Market

1.16USD
8:18pm IST
Change (% chg)

$-0.01 (-0.85%)
Prev Close
$1.17
Open
$1.20
Day's High
$1.20
Day's Low
$1.16
Volume
56,025
Avg. Vol
69,041
52-wk High
$4.25
52-wk Low
$1.16

Latest Key Developments (Source: Significant Developments)

Adamis Pharmaceuticals Announces Patent Litigation Regarding Its Higher Dose Naloxone Injection Product
Tuesday, 21 May 2019 

May 21 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS ANNOUNCES PATENT LITIGATION REGARDING ITS HIGHER DOSE NALOXONE INJECTION PRODUCT.ADAMIS PHARMACEUTICALS CORP - RECEIVED NOTICE THAT IT HAD BEEN NAMED AND SERVED AS A DEFENDANT IN A LAWSUIT FILED BY KALÉO INC.ADAMIS PHARMACEUTICALS - COMPLAINT ALLEGES CO'S PRODUCT CANDIDATE INFRINGES PATENTS PURPORTEDLY HELD BY KALÉO RELATING TO NALOXONE AUTO-INJECTOR PRODUCT.ADAMIS PHARMACEUTICALS CORP - ADAMIS DOES NOT ANTICIPATE STAY WOULD INTERRUPT OR DELAY FDA'S ONGOING REVIEW OF NDA.ADAMIS - IF PATENT DISPUTE IS UNRESOLVED BY THE TIME FDA PREPARED TO GRANT APPROVAL, AGENCY WOULD GRANT CONDITIONAL APPROVAL UNTIL SOONER OF OCT 4, 2021.ADAMIS PHARMACEUTICALS - BELIEVES NALOXONE INJECTION PRODUCT DOES NOT INFRINGE ANY VALID AND ENFORCEABLE PATENT HELD BY KALÉO.  Full Article

Adamis Pharmaceuticals Submits New Drug Application To FDA For Its Naloxone Pre-Filled Syringe
Tuesday, 1 Jan 2019 

Dec 31 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS SUBMITS NEW DRUG APPLICATION TO FDA FOR ITS NALOXONE PRE-FILLED SYRINGE.  Full Article

Adamis Pharmaceuticals Announces FDA Acceptance For Review For The Supplemental New Drug Application
Monday, 12 Feb 2018 

Feb 12 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE FOR REVIEW FOR THE SUPPLEMENTAL NEW DRUG APPLICATION OF ITS LOW DOSE SYMJEPI PRODUCT CANDIDATE.ADAMIS PHARMACEUTICALS CORP - FDA FURTHER INDICATED THAT NO POTENTIAL REVIEW ISSUES WERE IDENTIFIED.ADAMIS PHARMACEUTICALS CORP - FDA FURTHER INDICATED THAT NO POTENTIAL REVIEW ISSUES WERE IDENTIFIED.ADAMIS PHARMACEUTICALS CORP - FDA INDICATED IF NO MAJOR DEFICIENCIES IDENTIFIED, THEY ARE TARGETING SEPTEMBER 3, 2018 TO COMMUNICATE PROPOSED LABELING.  Full Article

Adamis Pharmaceuticals Announces Submission Of Investigational New Drug (Ind) Application To The FDA
Tuesday, 5 Dec 2017 

Dec 4 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION TO THE FDA FOR NEW PRODUCT CANDIDATE FOR THE TREATMENT OF OPIOID OVERDOSE.  Full Article

Adamis Pharma Submits Prior Approval Supplement To FDA For The Pediatric Version Of Symjepi
Thursday, 30 Nov 2017 

Nov 29 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS SUBMITS PRIOR APPROVAL SUPPLEMENT TO FDA FOR THE PEDIATRIC VERSION OF SYMJEPI.ADAMIS PHARMACEUTICALS CORP - SUBMISSION OF A PRIOR APPROVAL SUPPLEMENT TO U.S. FOOD AND DRUG ADMINISTRATION FOR PEDIATRIC VERSION (0.15MG) OF SYMJEPI.  Full Article

Novartis launches Adamis allergy shots in U.S. pharmacies amid EpiPen shortage

July 9 A unit of Novartis AG said on Tuesday it would make partner Adamis Pharmaceuticals Corp's emergency allergy shots immediately available in local pharmacies across the United States, amid a shortage of Mylan NV's rival product, EpiPen.